NCT07209189 2026-03-09
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
Clinical Trials
66 trialsNCT06975293 2026-03-05
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
STORM Therapeutics LTD
Phase 1/2 Recruiting
NCT06208826 2026-03-03
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06457503 2026-03-02
TRANSPARENT
Coherus Oncology, Inc.
Phase 4 Recruiting
NCT06592599 2026-02-10
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Stanford University
Phase 2 Recruiting
NCT07290621 2026-02-06
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
University of Chicago
Phase 2 Recruiting
NCT07371897 2026-01-28
SHINE
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07340515 2026-01-14
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
Shandong Cancer Hospital and Institute
Phase 3 Recruiting
NCT07258979 2025-12-02
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT07136519 2025-08-22
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
Affiliated Hospital of Guangdong Medical University
Phase 2 Not yet recruiting
NCT07110558 2025-08-07
PUPA
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05635643 2025-08-01
Study of CHS-114 in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Recruiting
NCT07088211 2025-07-31
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Recruiting
NCT05147844 2025-07-14
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Xinqiao Hospital of Chongqing
Phase 2 Recruiting
NCT06940180 2025-06-26
Toripalimab With Chemotherapy for Sinus Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06235203 2025-06-03
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Eye & ENT Hospital of Fudan University
Phase 3 Recruiting
NCT06987123 2025-05-23
TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06912711 2025-05-21
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06861712 2025-04-25
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT04517214 2025-04-02
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
Fudan University
Phase 2 Active not recruiting
NCT06712888 2025-03-18
Navigation
Sun Yat-sen University
Phase 3 Recruiting
NCT06851247 2025-02-28
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 2 Recruiting
NCT05869227 2024-12-30
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04996758 2024-12-12
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
Sun Yat-sen University
Phase 2 Completed
NCT03474640 2024-11-22
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Completed
NCT06647563 2024-10-18
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 3 Not yet recruiting
NCT06323239 2024-08-20
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06378177 2024-06-27
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Lyvgen Biopharma Holdings Limited
Phase 2 Recruiting
NCT05955105 2024-05-21
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
Phase 1/2 Recruiting
NCT06151743 2024-04-30
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 2 Recruiting
NCT06277050 2024-04-30
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Phase 3 Recruiting
NCT05773079 2024-04-01
Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT04473716 2023-11-22
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT05125055 2023-11-22
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Shanghai Jiao Tong University School of Medicine
Phase 2/3 Recruiting
NCT06081582 2023-10-13
Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT06039631 2023-09-15
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Fudan University
Phase 2 Recruiting
NCT06026878 2023-09-07
GNT Induction Treatment in Locally Advanced NPC
Air Force Military Medical University, China
Phase 3 Recruiting
NCT05993858 2023-08-15
PC-1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT04807140 2023-04-14
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT05813626 2023-04-14
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT05229315 2023-04-13
PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05803915 2023-04-07
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04405622 2023-02-06
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 2 Unknown
NCT04856631 2022-12-19
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05628922 2022-11-29
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Fudan University
Phase 2 Recruiting
NCT05340491 2022-08-31
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Sun Yat-sen University
Phase 3 Recruiting
NCT05484375 2022-08-02
Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT05420597 2022-06-15
Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma
Fudan University
Phase 2 Unknown
NCT04073784 2022-04-26
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 1 Unknown
NCT05341193 2022-04-22
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Unknown